Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib in Accelerated or Blastic Phase CML
NCT02511340Phase 2Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT02511340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511340.